Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Omeros Corp (OMER)

Omeros Corp (OMER)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 597,465
  • Shares Outstanding, K 57,950
  • Annual Sales, $ 0 K
  • Annual Income, $ -117,810 K
  • EBIT $ -173 M
  • EBITDA $ -172 M
  • 60-Month Beta 1.97
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 123.19% ( -12.30%)
  • Historical Volatility 226.06%
  • IV Percentile 91%
  • IV Rank 41.55%
  • IV High 274.89% on 04/05/24
  • IV Low 15.36% on 06/07/24
  • Put/Call Vol Ratio 0.21
  • Today's Volume 3,080
  • Volume Avg (30-Day) 3,167
  • Put/Call OI Ratio 0.50
  • Today's Open Interest 47,030
  • Open Int (30-Day) 40,763

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.63
  • Growth Rate Est. (year over year) +158,671.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.06 +70.13%
on 11/21/24
13.60 -24.19%
on 12/19/24
+4.28 (+70.98%)
since 11/20/24
3-Month
3.73 +176.41%
on 09/24/24
13.60 -24.19%
on 12/19/24
+6.39 (+163.01%)
since 09/20/24
52-Week
2.61 +294.72%
on 04/02/24
13.60 -24.19%
on 12/19/24
+7.32 (+244.82%)
since 12/20/23

Most Recent Stories

More News
Omeros: Q3 Earnings Snapshot

Omeros: Q3 Earnings Snapshot

OMER : 10.31 (+0.68%)
Omeros: Q2 Earnings Snapshot

Omeros: Q2 Earnings Snapshot

OMER : 10.31 (+0.68%)
Omeros: Q1 Earnings Snapshot

Omeros: Q1 Earnings Snapshot

OMER : 10.31 (+0.68%)
Omeros: Q4 Earnings Snapshot

Omeros: Q4 Earnings Snapshot

OMER : 10.31 (+0.68%)
Omeros: Q3 Earnings Snapshot

Omeros: Q3 Earnings Snapshot

OMER : 10.31 (+0.68%)
Omeros: Q2 Earnings Snapshot

Omeros: Q2 Earnings Snapshot

OMER : 10.31 (+0.68%)
Why Shares of Omeros Dropped on Monday

The clinical-stage biopharmaceutical released trials data through a presentation.

OMER : 10.31 (+0.68%)
Omeros: Q1 Earnings Snapshot

Omeros: Q1 Earnings Snapshot

OMER : 10.31 (+0.68%)
Omeros Corporation to Announce First Quarter Financial Results on May 9, 2023

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2023, on Tuesday, May 9, 2023, after the market closes....

OMER : 10.31 (+0.68%)
Omeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria

Omeros Corporation (Nasdaq: OMER) today announced positive results from a pre-specified interim analysis of its ongoing Phase 1b clinical trial of OMS906, the company’s lead MASP-3 inhibitor, in complement-inhibitor-naïve...

OMER : 10.31 (+0.68%)

Business Summary

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM)...

See More

Key Turning Points

3rd Resistance Point 14.82
2nd Resistance Point 13.82
1st Resistance Point 12.07
Last Price 10.31
1st Support Level 9.32
2nd Support Level 8.32
3rd Support Level 6.57

See More

52-Week High 13.60
Last Price 10.31
Fibonacci 61.8% 9.40
Fibonacci 50% 8.11
Fibonacci 38.2% 6.81
52-Week Low 2.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar